{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1+Condition+1&page=2", "query": { "intervention": "Phase 1 Condition 1", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1+Condition+1&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T10:53:53.700Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02606461", "title": "Selinexor in Advanced Liposarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 342, "start_date": "2016-01-04", "completion_date": "2021-10-26", "has_results": true, "last_update_posted_date": "2023-01-23", "last_synced_at": "2026-09-23T10:53:53.700Z", "location_count": 26, "location_summary": "Los Angeles, California • Santa Monica, California • Stanford, California + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02606461" }, { "nct_id": "NCT06029270", "title": "Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Nasopharyngeal Carcinoma", "Recurrent Nasopharyngeal Carcinoma", "Stage IV Nasopharyngeal Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Relatlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2024-07-15", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-23T10:53:53.700Z", "location_count": 83, "location_summary": "Dublin, California • Fremont, California • Fresno, California + 62 more", "locations": [ { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06029270" }, { "nct_id": "NCT01093183", "title": "Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Hormone-resistant Prostate Cancer", "Recurrent Prostate Cancer" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "MALE", "summary": "19 Years and older · Male only" }, "enrollment_count": 25, "start_date": "2010-03-04", "completion_date": "2015-05-19", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-09-23T10:53:53.700Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01093183" }, { "nct_id": "NCT00041054", "title": "Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "exisulind", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2002-06", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2016-12-07", "last_synced_at": "2026-09-23T10:53:53.700Z", "location_count": 81, "location_summary": "Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00041054" }, { "nct_id": "NCT03562494", "title": "VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "VY-AADC02", "type": "BIOLOGICAL" }, { "name": "Sham (Placebo) Surgery", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Neurocrine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 14, "start_date": "2018-10-17", "completion_date": "2024-10-30", "has_results": false, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-09-23T10:53:53.700Z", "location_count": 11, "location_summary": "Irvine, California • Sacramento, California • San Francisco, California + 8 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03562494" }, { "nct_id": "NCT06529822", "title": "Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Muscle-Invasive Bladder Carcinoma", "Gastroesophageal Adenocarcinoma", "Melanoma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Synthetic long peptide personalized cancer vaccine", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Signatera or Altera testing", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2025-03-20", "completion_date": "2034-06-30", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-23T10:53:53.700Z", "location_count": 3, "location_summary": "Orlando, Florida • St Louis, Missouri • Columbus, Ohio", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06529822" }, { "nct_id": "NCT01844622", "title": "Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Digestive System Disease" ], "interventions": [ { "name": "Domperidone", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mt. Sinai Medical Center, Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 37, "start_date": "2007-12", "completion_date": "2015-02-19", "has_results": false, "last_update_posted_date": "2017-05-16", "last_synced_at": "2026-09-23T10:53:53.700Z", "location_count": 2, "location_summary": "Miami Beach, Florida", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01844622" }, { "nct_id": "NCT02312622", "title": "Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Non-small Cell Lung Cancer (NSCLC)", "Recurrent Non-small Cell Lung Cancer (NSCLC)", "Extensive-stage Small Cell Lung Cancer (SCLC)", "Recurrent Small Cell Lung Cancer (SCLC)", "Tumors Metastatic to Brain", "Metastatic Breast Cancer (mBC)" ], "interventions": [ { "name": "Pegylated Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joel Neal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2015-08", "completion_date": "2019-07", "has_results": true, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-09-23T10:53:53.700Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02312622" }, { "nct_id": "NCT00079937", "title": "Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Omalizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fluticasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 628, "start_date": "2004-04", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2012-04-11", "last_synced_at": "2026-09-23T10:53:53.700Z", "location_count": 56, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079937" }, { "nct_id": "NCT00003796", "title": "Irofulven in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "irofulven", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 32, "start_date": "1999-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-09-23T10:53:53.700Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003796" } ] }